FY2025 EPS Estimates for Pfizer Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share (EPS) estimate for Pfizer from $3.15 to $3.05, while the consensus estimate stands at $2.95 EPS.
• Several analysts have recently adjusted their price targets and ratings for Pfizer, with Citigroup raising its target to $26.00 and Morgan Stanley reducing it to $32.00.
• Pfizer announced a quarterly dividend of $0.43 per share, payable on December 1, 2025, representing a 6.9% yield based on current valuations.

Pfizer Inc. (NYSE:PFE - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Pfizer in a research note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of $3.05 per share for the year, down from their previous forecast of $3.15. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer's FY2026 earnings at $3.09 EPS.

PFE has been the topic of several other reports. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Finally, Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus price target of $28.35.

Pfizer Stock Performance

PFE opened at $24.81 on Monday. The firm has a market capitalization of $141.03 billion, a PE ratio of 13.19, a PEG ratio of 0.82 and a beta of 0.55. Pfizer has a twelve month low of $20.92 and a twelve month high of $29.82. The firm's 50-day moving average price is $24.86 and its 200 day moving average price is $24.12. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's dividend payout ratio is presently 91.49%.

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $27,000. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in Pfizer in the second quarter valued at $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.